Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Disease

Lewy Body Disease

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 6, 2026 · PHASE 2 TRIAL

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

ClinicalTrials.gov

This is a Phase 2 clinical trial registry record with no reported results; it describes a planned study design and enrollment target only.

PreliminaryEli Lilly and Company Donanemab NCT07589595

Reported

Estimated enrollment350

Primary outcome measureChange from Baseline on Clinical Dementia R…

Study phasePhase 2

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support